slides · global inventory
Solution
Slide type collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 8,880
Current window 6,031-6,060
Pages 296
Rows per page 30
Slide type
6,031-6,060 of 8,880
50
Exscientia | Investor Presentation Deck | 76 slidesExscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
51
The slide uses a three-column layout to define the technical requirements for the drug candidate.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
54
The chart illustrates a Pareto front in drug discovery, highlighting that the 'best' molecules (on the front) are not always the most information-rich for further development.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
55
The slide uses two distinct chart types (dot plot and line chart with error bars) to demonstrate safety advantages.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
59
Includes a heatmap showing synergy scores across cell lines and two dose-response line charts showing increased inhibition in combination.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
64
Exscientia | Investor Presentation Deck | 76 slidesExscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
65
Scientific diagram showing the BCR and TLR signaling pathways converging on MALT1 and NF-kB.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
66
The slide uses a three-column layout to define the core pillars of the drug development strategy.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
70
The slide highlights the technical methodology behind the 565 candidate development, specifically focusing on allosteric site constraints and permeability.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
72
The slide uses two dose-response curves to demonstrate selectivity.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
03
The slide uses a collage of imagery representing political and legislative processes to reinforce the 'What We Do' statement.FiscalNote | Investor Presentation Deck | 33 slides · FiscalNote
Pitch deck Investor relations Beat · Solution1 hit
05
The slide uses a process flow diagram to map risks onto a supply chain journey.FiscalNote | Investor Presentation Deck | 33 slides · FiscalNote
Pitch deck Investor relations Beat · Solution1 hit
11
FiscalNote | Investor Presentation Deck | 33 slidesFiscalNote | Investor Presentation Deck | 33 slides · FiscalNote
Pitch deck Investor relations 1 hit
12
The slide uses a process flow diagram to illustrate the company's proprietary data infrastructure.FiscalNote | Investor Presentation Deck | 33 slides · FiscalNote
Pitch deck Investor relations 1 hit
14
Uses a tree metaphor for the left side (core tech) and a grid for the right side (target sectors).FiscalNote | Investor Presentation Deck | 33 slides · FiscalNote
Pitch deck Investor relations 1 hit
10
Uses travel industry analogies (Amadeus/Sabre and Booking.com/Expedia) to explain the business model.Freightos | Investor Presentation Deck | 34 slides · Freightos
Pitch deck Investor relations Beat · Solution1 hit
15
The slide uses a PET scan image to demonstrate selective tumor uptake versus normal tissue, and a table to quantify market opportunity by tumor type.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
19
The slide uses a combination of a process diagram for the in vivo study and a line chart to show efficacy results.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
29
The slide uses a spectrum chart to show increasing potency of toxins and a table to list advantages of TATs over ADCs.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
30
The slide uses a process diagram to show the excretion pathway and a line chart to demonstrate the 3.1x improvement in excretion rate compared to a commercial linker.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
11
Hagerty | Investor Presentation Deck | 24 slidesHagerty | Investor Presentation Deck | 24 slides · Hagerty
Pitch deck Investor relations Beat · Solution1 hit
04
Hyperfine | Investor Presentation Deck | 22 slidesHyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
05
Uses a before-after framing to contrast traditional centralized MRI with the decentralized Swoop system.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
09
Uses a comparison framework to demonstrate efficiency gains.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations 1 hit
15
The central icon represents the Hyperfine device, surrounded by five service/support pillars.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations 1 hit
11
The slide uses a process flow diagram to show how different AI capabilities contribute to productivity, quality, and volume boosts.IBEX | Investor Presentation Deck | 18 slides · ibex
Pitch deck Investor relations Beat · Rising SuccessLoop · Quick Win Big Bet1 hit
05
The slide uses a split-screen visual comparison to contrast traditional antibody approaches with the company's TCR-based platform.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Problem1 hit
13
The slide uses a combination of a biological mechanism diagram, a checklist of target criteria, and histological images to validate the therapeutic target.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
14
The slide uses a circular process diagram to illustrate the therapy lifecycle, followed by a zoomed-in molecular interaction diagram.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
26
The slide uses a biological diagram to illustrate the synergy between CD4 and CD8 T cells in inducing tumor cell death.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit